Aon PLC vs Cytokinetics Inc — how do they compare? Aon PLC trades at $356.48 (market cap $75.72B), while Cytokinetics Inc trades at $77.39 (market cap $10.78B). The key difference: Aon PLC is far larger — about 7× Cytokinetics Inc's market cap, and Aon PLC pays a 0.92% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AON | CYTK | |
|---|---|---|
Market Cap | $75.72B | $10.78B |
Sector | Financials | Technology |
52-Week High | $381.26 | $87.26 |
52-Week Low | $308.22 | $34.31 |
Enterprise Value | $90.33B | $10.88B |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
AON trades at $358.3, down 0.68% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.81 versus $3.8 expected, driven by 5% organic revenue growth. Valuation metrics include a P/E of 19.75 and P/S of 4.39, while profitability remains robust with a net income margin of 22.27% and ROE of 44.88%. Recent news highlights institutional buying and a new executive appointment.
The outlook is positive with a consensus price target of $410, implying 14% upside, supported by earnings momentum and solid cash flow. Risks include premium valuation concerns and modest organic growth. Analyst sentiment is balanced with 47% buy ratings, but high debt levels and competitive pressures warrant caution for investors.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →